We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SONY Unveils Self-Fitting CRE-C10 & CRE-E10 OTC Hearing Aid
Read MoreHide Full Article
Sony Group Corporation (SONY - Free Report) has launched two new self-fitting over-the-counter (OTC) hearing aid for customers in the United States in collaboration with WS Audiology. The CRE-C10 and CRE-E10 hearing aid are priced at $999.99 and $1299.99, respectively.
Customers can set up and begin using either device by pairing it with Sony's Hearing Control App. The application allows the hearing aid to interact with the user's smartphone, enabling them to customize and adjust settings like volume control and more.
The application also allows the wearer to "self-fit" each device. The new device self-adjusts to the most suitable pre-defined hearing profiles throughout the in-app self-fitting process. These pre-defined hearing profiles are based on thousands of genuine and real-world audiogram data.
The CRE-E10 features an earbud-like design and is Bluetooth compatible, letting users to stream audio or music. It also has a rechargeable battery which lasts up to 26 hours, whereas the CRE-C10 has a battery life of 70 hours, per company report.
The hearing aids are designed to eliminate obstacles faced by people with signs of mild to moderate hearing loss. Both devices are available on the company’s website and through various retailers like Amazon, Best Buy and select hearing-care professionals.
SONY has been focusing on developing new products within the lucrative medical/healthcare vertical.
Recently, Sony collaborated with Olympus Corporation and Sony Olympus Medical Solutions to develop a surgical endoscopy system that enables surgeons to use 4K, 3D, Infrared Imaging and Narrow Band Imaging.
The system is also compatible with Olympus' existing product portfolio, such as rigid scopes, flexible scopes and camera heads to treat tumors and lesions. It can also be upgraded and used for general surgery, urology, gynecology, and Ear, Nose and Throat surgery.
Sony designs, manufactures and sells several consumer and industrial electronic equipment. For fiscal 2022, the company expects sales of ¥11,500 billion, up 16% year over year compared with ¥11,400 billion guided earlier.
The company decreased its outlook for net income from ¥830 billion to ¥800 billion, declining 9% year over year. Also, it expects the operating margin for the fiscal year to be likely affected by a decline in Pictures and Game & Network Services segment operating incomes.
Sony currently has a Zacks Rank #3 (Hold). The stock has lost 42.3% in the past year compared with the industry’s decline of 43.4%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the broader consumer discretionary sector are RCI Hospitality (RICK - Free Report) , Swedish Match and Lululemon Athletica (LULU - Free Report) . RCI Hospitality, Swedish Match and Lululemon Athletica each sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks.
The Zacks Consensus Estimate for RCI Hospitality’s 2022 earnings is pegged at $5.15 per share, unchanged in the past 60 days. The long-term earnings growth rate is anticipated to be 12%.
RCI Hospitality’s earnings beat the Zacks Consensus Estimate in three of the last four quarters, the average being 39.4%. Shares of RICK have increased 1.1% in the past year.
The Zacks Consensus Estimate for Swedish Match’s 2022 earnings is pegged at 46 cents per share, up 2.2% in the past 60 days.
Swedish Match’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 10.7%. Shares of SWMAY have increased 1.6% in the past year.
The Zacks Consensus Estimate for Lululemon’s 2022 earnings is pegged at $9.88 per share, up 4.7% in the past 60 days. The long-term earnings growth rate is anticipated to be 20%.
Lululemon’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 10.4%. Shares of LULU have decreased 27.4% in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
SONY Unveils Self-Fitting CRE-C10 & CRE-E10 OTC Hearing Aid
Sony Group Corporation (SONY - Free Report) has launched two new self-fitting over-the-counter (OTC) hearing aid for customers in the United States in collaboration with WS Audiology. The CRE-C10 and CRE-E10 hearing aid are priced at $999.99 and $1299.99, respectively.
Customers can set up and begin using either device by pairing it with Sony's Hearing Control App. The application allows the hearing aid to interact with the user's smartphone, enabling them to customize and adjust settings like volume control and more.
The application also allows the wearer to "self-fit" each device. The new device self-adjusts to the most suitable pre-defined hearing profiles throughout the in-app self-fitting process. These pre-defined hearing profiles are based on thousands of genuine and real-world audiogram data.
Sony Corporation Price and Consensus
Sony Corporation price-consensus-chart | Sony Corporation Quote
The CRE-E10 features an earbud-like design and is Bluetooth compatible, letting users to stream audio or music. It also has a rechargeable battery which lasts up to 26 hours, whereas the CRE-C10 has a battery life of 70 hours, per company report.
The hearing aids are designed to eliminate obstacles faced by people with signs of mild to moderate hearing loss. Both devices are available on the company’s website and through various retailers like Amazon, Best Buy and select hearing-care professionals.
SONY has been focusing on developing new products within the lucrative medical/healthcare vertical.
Recently, Sony collaborated with Olympus Corporation and Sony Olympus Medical Solutions to develop a surgical endoscopy system that enables surgeons to use 4K, 3D, Infrared Imaging and Narrow Band Imaging.
The system is also compatible with Olympus' existing product portfolio, such as rigid scopes, flexible scopes and camera heads to treat tumors and lesions. It can also be upgraded and used for general surgery, urology, gynecology, and Ear, Nose and Throat surgery.
Sony designs, manufactures and sells several consumer and industrial electronic equipment. For fiscal 2022, the company expects sales of ¥11,500 billion, up 16% year over year compared with ¥11,400 billion guided earlier.
The company decreased its outlook for net income from ¥830 billion to ¥800 billion, declining 9% year over year. Also, it expects the operating margin for the fiscal year to be likely affected by a decline in Pictures and Game & Network Services segment operating incomes.
Sony currently has a Zacks Rank #3 (Hold). The stock has lost 42.3% in the past year compared with the industry’s decline of 43.4%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the broader consumer discretionary sector are RCI Hospitality (RICK - Free Report) , Swedish Match and Lululemon Athletica (LULU - Free Report) . RCI Hospitality, Swedish Match and Lululemon Athletica each sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks.
The Zacks Consensus Estimate for RCI Hospitality’s 2022 earnings is pegged at $5.15 per share, unchanged in the past 60 days. The long-term earnings growth rate is anticipated to be 12%.
RCI Hospitality’s earnings beat the Zacks Consensus Estimate in three of the last four quarters, the average being 39.4%. Shares of RICK have increased 1.1% in the past year.
The Zacks Consensus Estimate for Swedish Match’s 2022 earnings is pegged at 46 cents per share, up 2.2% in the past 60 days.
Swedish Match’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 10.7%. Shares of SWMAY have increased 1.6% in the past year.
The Zacks Consensus Estimate for Lululemon’s 2022 earnings is pegged at $9.88 per share, up 4.7% in the past 60 days. The long-term earnings growth rate is anticipated to be 20%.
Lululemon’s earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 10.4%. Shares of LULU have decreased 27.4% in the past year.